01—Abstract
Summary
Summary of the 8-K filed August 10, 2026. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported second quarter 2026 results on August 10, 2026, furnished as Exhibit 99.1 to this Form 8-K under Item 2.02.
Total revenues, net were $243.7 milliona for the quarter, comprised of $222.4 million of U.S. Attruby net product revenue, $15.4 million of royalty revenue, and $5.8 million of license and services revenue, compared with $110.6 million in the same period of 2025. Total operating costs and expenses rose to $350.8 million from $244.8 million, and the net loss attributable to common stockholders of BridgeBio was $152.2 million, or $0.78 per share, versus $181.9 million, or $0.95 per share, a year earlier. The company reported $720.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026, excluding a $1 billion preferred equity financing led by Sixth Street that closed on July 1, 2026.
The company states that all three planned NDAs have now been submitted to the FDA: BBP-418 for LGMD2I/R9 and encaleret for ADH1 were each accepted with Priority Review, with PDUFA target dates of November 27, 2026 and May 8, 2027, respectively, and no advisory committee planned for either. Oral infigratinib for achondroplasia has been submitted, with a U.S. launch expected in mid-2027.
Management highlighted new kidney-related post-hoc analyses for Attruby published in Circulation: Heart Failure, along with real-world evidence comparing acoramidis with tafamidis. The company also noted a Commercial Day in New York City on October 8, 2026, and ongoing pipeline expansion efforts including RECLAIM-HP, CALIBRATE-PEDS, and a hypochondroplasia Phase 2 update expected in the second half of 2026.
02—Key points
Key Highlights
- Total revenues, net of $243.7 million for Q2 2026, up from $110.6 million in Q2 2025, driven by $222.4 million of U.S. Attruby net product revenue.
- Total operating costs and expenses of $350.8 million for Q2 2026 versus $244.8 million a year earlier, with SG&A of $186.3 million and R&D of $149.4 million.
- Net loss attributable to common stockholders of BridgeBio of $152.2 million, or $0.78 per share, for Q2 2026, compared with $181.9 million, or $0.95 per share, in Q2 2025.
- Cash, cash equivalents, and marketable securities of $720.2 million as of June 30, 2026, excluding the $1 billion preferred equity financing that closed July 1, 2026.
- BBP-418 (LGMD2I/R9) NDA accepted with Priority Review, PDUFA date November 27, 2026; encaleret (ADH1) NDA accepted with Priority Review, PDUFA date May 8, 2027; both with no advisory committee planned.
- Oral infigratinib for achondroplasia NDA submitted to the FDA, with a U.S. launch expected in mid-2027.
- New Attruby post-hoc kidney analyses published in Circulation: Heart Failure, and a Commercial Day in New York City scheduled for October 8, 2026.
03—Questions
Frequently Asked Questions
How much revenue did BridgeBio generate in the second quarter of 2026, and what drove the change?
Total revenues, net were $243.7 million for the three months ended June 30, 2026, compared with $110.6 million a year earlier. The $133.1 million increase was primarily driven by a $150.9 million increase in Attruby net product revenue and a $13.8 million increase in royalty revenue from BEYONTTRA sales in the EU and Japan, partially offset by lower license and services revenue due to $30.0 million of regulatory milestone revenue recognized in Q2 2025.
What is the company's cash position following the recent financing?
Cash, cash equivalents, and marketable securities totaled $720.2 million as of June 30, 2026, up from $587.5 million at December 31, 2025. This figure does not include the $1 billion preferred equity financing led by Sixth Street, with participation from HealthCare Royalty, an affiliate of KKR, which closed on July 1, 2026.
What regulatory milestones are upcoming for BridgeBio's pipeline?
BBP-418 for LGMD2I/R9 has a PDUFA target action date of November 27, 2026, and encaleret for ADH1 has a PDUFA date of May 8, 2027, both under Priority Review with no advisory committee planned. Oral infigratinib for achondroplasia has been submitted to the FDA, which will set a PDUFA date, and the company anticipates a U.S. launch in mid-2027.
What drove the increase in operating expenses and the net loss?
Total operating costs and expenses rose $106.0 million to $350.8 million, primarily due to a $57.1 million increase in SG&A expenses reflecting Attruby commercialization and pre-commercial activities for Phase 3 candidates, a $38.2 million increase in R&D expenses, and an $11.4 million increase in cost of revenues. Total other expense, net was $(48.8) million, including a $15.3 million increase in noncash interest expense on deferred royalty obligations, which contributed to the net loss attributable to common stockholders of $152.2 million.
04—Continue